Reported about 3 hours ago
In a recent discussion, Goldman Sachs' Chris Shibutani offered insights into how to navigate biotech and pharmaceutical stocks, focusing on Johnson & Johnson and Pfizer. With J&J about to report earnings, Shibutani emphasized its importance as a bellwether for the sector due to its diverse business model. He notes the company's strategic direction in medtech and the potential impact of biosimilars. Regarding Pfizer, he highlighted its past peak during the pandemic and current underperformance, suggesting that activist investor interest may rise as the company grapples with recent challenges.
Source: YAHOO